 Over all, the animals treated with anti-diabetic agents in combination showed better response.
End of study. Bleeding and liver collection.
Biochemical parameter analysis.
Experimental design D. Vildagliptin 10 mg/kg
Grouping based on body weight Biochemical parameters were determined by colorimetric assay. At the end of the experiment animals were sacrificed, liver samples collected and subjected to histopathological examination and triglyceride estimation.
The animals treated with anti-diabetic agents in combination showed better efficacy than any given alone. Vildagliptin and rosiglitazone combination group showed significant reduction in fasting plasma glucose (P<0.05), hepatic steatosis (P<0.05) and liver triglycerides (P<0.01). Though the vildagliptin and metformin combination showed significant reduction in body weight gain (P<0.01) from 12 th day of treatment, but did not show reduction in hepatic steatosis and triglycerides.
In conclusion, animals treated with vildagliptin and rosiglitazone in combination showed significant reduction in hepatic steatosis and triglycerides. Our data suggests that combination therapy of a DPP IV inhibitor with a PPAR- agonist may be a new therapeutic strategy for the treatment of NAFLD.
 Non-alcoholic fatty liver disease (NAFLD) is a leading cause of liver dysfunction, develops in the absence of alcohol abuse.
 NAFLD includes a spectrum of alterations that range from simple accumulation of fat in the liver exceeding 5-10 % by weight (steatosis), to non-alcoholic steatohepatitis (NASH) and advanced fibrosis which can lead to cirrhosis, liver failure and hepatocellular carcinoma.
 NAFLD is considered as hepatic manifestation of insulin resistance (IR), and strongly associated with metabolic disorders such as type 2 diabetes, obesity and dyslipidemia.
 Since disease is multifactor origin and importantly, insulin resistance plays a fundamental role in development of NAFLD, for effective therapy combination of antidiabetic agents which are acting through different mechanisms may be a logical approach. Hence the present study was designed to assess the effect of vildagliptin alone (DPP-IV Inhibitor) and in combination with metformin (Biguanide) and rosiglitazone (PPAR- agonist) in diet induced NAFLD in C57BL/6 mice.
h fasting

n=7-10
Male C57BL/6 mice aged 5-6 weeks and body weight ranges 24.29 ± 0.29 g were used for the study.
Animals were divided into two groups, first group (n=12) fed with chow feed and the second group (n =65) was fed with high fat diet (60 Kcal %) and high fructose (40 %) in drinking water for 60 days. After 45 th day, 2 animals from each group were sacrificed and liver histopathology examination carried out to confirm the induction of NAFLD.
After completion of induction period, animals were further divided into different groups, (Table No- 
